Pao-Yu Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pao-Yu Chen has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
Yee-Chun Chen
4 shared publications- Yee-Chun Chen
Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital , Taipei
3 shared publications - Ming-Tao Tsai
Department of Medicine, National Taiwan University Cancer Center
2 shared publications - Tzong-Yow Wu
Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan
2 shared publications Alberto Vega Hernández
1 shared publicationAleksandra Barac
1 shared publication
Latest Publications
- Open Access
- 16 September 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 100
Treatment and outcome of chronic disseminated candidiasis in the era of antifungal prophylaxis: a retrospective multicentre cohort of 111 patients
- 16 September 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 100
Open AccessTreatment and outcome of chronic disseminated candidiasis in the era of antifungal prophylaxis: a retrospective multicentre cohort of 111 patients
- Open Access
- 1 September 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (5)
Performance of the Sensititre YeastOne assay compared with EUCAST E.Def 9.4 against Fusarium clinical isolates: focus on voriconazole and amphotericin B
Objectives: Despite the global emergence of Fusarium infections, data validating commercial antifungal susceptibility testing against these moulds remain scarce. We evaluated the performance and optimal reading time of the Sensititre YeastOne (SYO) assay against Fusarium clinical isolates compared with the EUCAST reference method. Methods: This two-centre study (2011–2023) analysed 123 Fusarium isolates identified via two-step molecular sequencing. In vitro susceptibilities to voriconazole and amphotericin B were evaluated using SYO (24 h and 48 h readouts) versus the EUCAST E.Def 9.4 broth microdilution reference method (48 h readout). Essential agreement (EA) was defined as a ±2 log2 dilution difference; >90% was acceptable. Results: Fusarium solani species complex (FSSC) dominated the cohort (85.3%), predominantly F. keratoplasticum and F. pseudensiforme. EUCAST testing revealed high MIC50/MIC90 values of voriconazole (>16/>16 mg/L) and amphotericin B (2/16 mg/L). While 65% (80/123) of isolates displayed positivity by SYO at 24 h, median spectrophotometric growth was significantly greater at 48 h than at 24 h [0.37 (IQR 0.315–0.403) versus 0.18 (0.151–0.206)]. At 48 h, EA approached acceptability for voriconazole (92.7%) and amphotericin B (89.4%). Voriconazole categorical agreement (CA) among FSSC was 88.6% and reached 96.9% for F. pseudensiforme. For amphotericin B, SYO MICs clustered around 4–8 mg/L, yielding 100% very major error for F. keratoplasticum and F. pseudensiforme but 100% CA for F. falciforme, F. petroliphilum and non-FSSC. Conclusions: Voriconazole and amphotericin B susceptibility determined by SYO cannot universally replace reference methods due to failure to detect non-WT to amphotericin B for prevalent species within FSSC. However, alongside accurate species-level molecular identification, SYO provides actionable susceptibility data for validated species-antifungal combinations.
- 1 September 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (5)
Open AccessPerformance of the Sensititre YeastOne assay compared with EUCAST E.Def 9.4 against Fusarium clinical isolates: focus on voriconazole and amphotericin B
Objectives: Despite the global emergence of Fusarium infections, data validating commercial antifungal susceptibility testing against these moulds remain scarce. We evaluated the performance and optimal reading time of the Sensititre YeastOne (SYO) assay against Fusarium clinical isolates compared with the EUCAST reference method. Methods: This two-centre study (2011–2023) analysed 123 Fusarium isolates identified via two-step molecular sequencing. In vitro susceptibilities to voriconazole and amphotericin B were evaluated using SYO (24 h and 48 h readouts) versus the EUCAST E.Def 9.4 broth microdilution reference method (48 h readout). Essential agreement (EA) was defined as a ±2 log2 dilution difference; >90% was acceptable. Results: Fusarium solani species complex (FSSC) dominated the cohort (85.3%), predominantly F. keratoplasticum and F. pseudensiforme. EUCAST testing revealed high MIC50/MIC90 values of voriconazole (>16/>16 mg/L) and amphotericin B (2/16 mg/L). While 65% (80/123) of isolates displayed positivity by SYO at 24 h, median spectrophotometric growth was significantly greater at 48 h than at 24 h [0.37 (IQR 0.315–0.403) versus 0.18 (0.151–0.206)]. At 48 h, EA approached acceptability for voriconazole (92.7%) and amphotericin B (89.4%). Voriconazole categorical agreement (CA) among FSSC was 88.6% and reached 96.9% for F. pseudensiforme. For amphotericin B, SYO MICs clustered around 4–8 mg/L, yielding 100% very major error for F. keratoplasticum and F. pseudensiforme but 100% CA for F. falciforme, F. petroliphilum and non-FSSC. Conclusions: Voriconazole and amphotericin B susceptibility determined by SYO cannot universally replace reference methods due to failure to detect non-WT to amphotericin B for prevalent species within FSSC. However, alongside accurate species-level molecular identification, SYO provides actionable susceptibility data for validated species-antifungal combinations.
- Open Access
- 1 September 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (5)
Invasive pulmonary aspergillosis caused by a rare species of Aspergillus turcosus : case report and literature review
- 1 September 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (5)
Open AccessInvasive pulmonary aspergillosis caused by a rare species of Aspergillus turcosus : case report and literature review
- Open Access
- 26 August 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1)
Epidemiology and outcomes of invasive fungal infections in patients with mature T-cell and NK-cell lymphomas
Invasive fungal infections (IFIs) remain a major cause of morbidity and mortality among patients with haematological malignancies [1], particularly those with acute leukaemia [2] and haematopoietic...
- 26 August 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1)
Open AccessEpidemiology and outcomes of invasive fungal infections in patients with mature T-cell and NK-cell lymphomas
Invasive fungal infections (IFIs) remain a major cause of morbidity and mortality among patients with haematological malignancies [1], particularly those with acute leukaemia [2] and haematopoietic...
- Open Access
- 6 February 2026
- Published by Elsevier in CMI Communications
- Vol. 3 (1)
Thyroid aspergillosis: A narrative review
- 6 February 2026
- Published by Elsevier in CMI Communications
- Vol. 3 (1)
Open AccessThyroid aspergillosis: A narrative review
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
2887. Implication of genotypes for prognosis of Candida glabrata bloodstream infections
Genotyping a specific pathogen may demonstrate unique patterns of antimicrobial resistance and/or interaction between pathogen and host, which subsequently lead to miserable consequence. Herein, we conducted a retrospective single-center study to analyze the association between genotypes and clinical outcomes among Candida glabrata bloodstream infections (BSIs). A standard case report form was used to collect the clinical data of hospitalized adults with C. glabrata BSIs in 2017. Antifungal susceptibility testing was performed by using the Sensititre YeastOne SYO-10 panel, and minimum inhibitory concentrations (MICs) were interpretated according to the Clinical and Laboratory Standard Institute. Genotyping was performed by using a multilocus sequence typing scheme, and further analyzed by the unweighted pair group method with arithmetic averages (UPGMA) method. Comparison of Kaplan–Meier survival curves between cloncal complex 7 (CC7) and non-cloncal complex 7 (non-CC7) at 28 days in patients with Candida glabrata bloodstream infections Our data shed light on the impact of genotypes on clinical outcomes in C. glabrata BSIs. Further virulence characterization of CC7 is warranted. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access2887. Implication of genotypes for prognosis of Candida glabrata bloodstream infections
Genotyping a specific pathogen may demonstrate unique patterns of antimicrobial resistance and/or interaction between pathogen and host, which subsequently lead to miserable consequence. Herein, we conducted a retrospective single-center study to analyze the association between genotypes and clinical outcomes among Candida glabrata bloodstream infections (BSIs). A standard case report form was used to collect the clinical data of hospitalized adults with C. glabrata BSIs in 2017. Antifungal susceptibility testing was performed by using the Sensititre YeastOne SYO-10 panel, and minimum inhibitory concentrations (MICs) were interpretated according to the Clinical and Laboratory Standard Institute. Genotyping was performed by using a multilocus sequence typing scheme, and further analyzed by the unweighted pair group method with arithmetic averages (UPGMA) method. Comparison of Kaplan–Meier survival curves between cloncal complex 7 (CC7) and non-cloncal complex 7 (non-CC7) at 28 days in patients with Candida glabrata bloodstream infections Our data shed light on the impact of genotypes on clinical outcomes in C. glabrata BSIs. Further virulence characterization of CC7 is warranted. All Authors: No reported disclosures